Does anyone have any information that they can post here about my questions after trying to get an idea of what might be going on?
-- whether patients who were already on the Eversense Continuous Glucose Monitor are switching away? Because of the pandemic or what other reasons? I recall reading that a high percentage of patients were, before the pandemic, staying with it, and, I heard in the latest investor conference call that the pandemic consequences included shutting down any new patient initiations. Okay, no new patients starting, but, what about prior patients remaining and getting their next replacement by staying with Eversense? If patients WANT to stay on Eversense in all this chaos, I want to know; do you?
-- why there was such a large write-off for obsolete inventory in the quarterly report just out? I am wondering, specifically, if that means discontinued finished/components of a model (for example, writing off the inventory that would have been only devoted to the shorter time model rather than the future longer lasting model (change from three months to six or even twelve months between changing by patient))? In other words, is it reasonable to believe SENS is already taking hits to evolve to its future models?
-- if the providers, the diabetic endocrinologists, have decided "to be or not to be" trained to provide Eversense to their patients? I get it that arranging training was futile during the height of the pandemic lock-downs, and that the training staff has all been let go, right? I am more curious if the provider community is even wanting to be trained: After all, if past patients demand staying on the Everense, and, if new patient interest is there, that means training gets retarted, right? Okay, I get it, the question is insurance coverage, so likely any real surge is dependent on more generous coverage, yes, but, does anyone have a sense to share if providers are intending, in a world after pandemic, to aid training and qualifying to dispense their prescribing Eversense to their clinic patients?
-- are rivals with or without loyalty for refills? I get it that there is no real "apple to apple" comparison to any rivalry, but, whatever else is in use, at least in old material on the website, was not getting as high a refill rate, so patients moving towards the use of Eversense seemed underway before killed off by the pandemic, right?
-- is the precarious financial plight a kiss of death? In other words, a sort of self-fulfilling prophecy might be unfolding? The question: will providers and patients stay away because of the insolvency facing SENS?
AI
